Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Approval Status Update for PERCOCET (ANDA040330)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:33:17 PM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of PERCOCET under ANDA040330 is a significant regulatory milestone that could strengthen OZANTRI's competitive position in the opioid pain management market. Portfolio teams must assess the implications for market share and competitive strategies in light of this approval. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 8 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the impact of this approval on market share and consider strategies for competitive positioning. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 2 competitive items passed relevance filtering for PERCOCET.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance OZANTRI's position in the pain management market, particularly in the opioid segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The approval status indicates compliance with FDA requirements, but ongoing monitoring of market launch and sales performance will be essential to ensure sustained regulatory alignment.

Key Risks

Elevated medium regulatory exposure for PERCOCET could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for OZANTRI in the opioid segment, potentially impacting revenue streams and competitive dynamics in pain management.
Portfolio teams should evaluate the impact of this approval on market share and consider strategies for competitive positioning.

What Would Change This Assessment

This becomes more urgent if Monitor for any further updates on market launch and sales performance of the approved product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — PERCOCET (SUPPL)
FDAmedium relevance
Entity match (percocet); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAlow relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PERCOCET
OZANTRI

Commercial impact

medium

The approval could lead to increased market share for OZANTRI in the opioid segment, potentially impacting revenue streams and competitive dynamics in pain management.

Regulatory impact

medium

The approval status indicates compliance with FDA requirements, but ongoing monitoring of market launch and sales performance will be essential to ensure sustained regulatory alignment.

What to watch

Monitor for any further updates on market launch and sales performance of the approved product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.